EUPATI announced that its second workshop will take place on April 2, 2014 at the Hotel InterContinental Warszawa, Poland.
The European Patients’ Academy on Therapeutic Innovation (EUPATI) has announced that its second workshop, “Reaching a Public Audience on Medicines Development,” will take place on April 2, 2014 at the Hotel InterContinental Warszawa, Poland.
The workshop has been designed to draw on EUPATI’s social research work involving patients and citizens across Europe, as well as to hear views from patient advocates and the public and to provide details about successful examples of information sharing. Among the attendees are likely to be representatives from stakeholder groups that have a role in the medicines development process, including patients, industry, academia, ethics committees, regulators, and medical professionals.
According to the organizers, “Breakout sessions will be used for brainstorming on the best ways to inform patients and citizens about medicines research and development. We want each workshop delegate to advise us on how EUPATI can meet the information needs of the patient community and provide information appropriately. Throughout the workshop you will have many opportunities to voice your opinions and share your thoughts. We strongly encourage open and active dialogues in Warsaw!”
EUPATI is funded by the Innovative Medicines Initiative, and aims to provide scientifically reliable, objective, comprehensive information to patients on medicines research and development. It seeks to increase the capacities and capabilities of well-informed patients and patient organizations to be effective advocates and advisors in medicines research.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.